Gå direkt till innehåll
Anna Hill, Clinical Operations Manager at Scandinavian Biopharma
Anna Hill, Clinical Operations Manager at Scandinavian Biopharma

Pressmeddelande -

Scandinavian Biopharma recruits Anna Hill as Clinical Operations Manager

Scandinavian Biopharma is now strengthening its organization by recruiting Anna Hill to the new position as Clinical Operations Manager. The company is in late clinical development phase with several ongoing clinical studies for the ETEC vaccine candidate ETVAX®. Anna will have the overall responsibility for the company's clinical development program and be responsible for ensuring that ongoing and future clinical trials are performed in a compliant and efficient manner. Anna has solid experience from similar positions at pharmaceutical companies such as Moberg Pharma and Amgen.

- To be able to implement our ambitious clinical development program we needs to strengthen the organisation within Clinical Operations. Anna's experience and skills will be very important for us and I am very pleased to welcome her to Scandinavian Biopharma, says Björn Sjöstrand, CEO of Scandinavian Biopharma.

- I am very excited to contribute in developing the clinical trial business of an innovative and expanding company like Scandinavian Biopharma. I really look forward to be a part in the development of a vaccine that significantly can have an impact on the global health. In this position I can combine my past experiences with the strong driving force that exists at Scandinavian Biopharma”, says Anna Hill.

Initially, Anna's focus will be on ETVAX® clinical trial programs in Africa. In 2019, a phase I study was started in Zambia aiming to establish the optimal dose of ETVAX® for children and to investigate the benefits of a booster dose. The Zambia study will be followed by a Phase IIb study in Gambia with the aim of establishing the safety, immune response and protective effect of ETVAX®.

Ämnen

Kategorier


Scandinavian Biopharma

We are a research-based specialty biopharma company determined to give people worldwide a longer and better life.

We are developing the first vaccine for protection against diarrhoea caused by ETEC in both travellers and endemic populations.

We distribute a wide range of specialty biopharma products with focus on vaccines and immunoglobulins.

www.scandinavianbiopharma.se

Kontakter

Björn Sjöstrand

Björn Sjöstrand

Presskontakt VD +46 (0)72 712 51 20

Relaterat innehåll

Vi är ett forskningsbaserat biotechföretag fast beslutna att ge människor i hela världen ett längre och bättre liv.

Vi utvecklar det första vaccinet i världen mot diarré orsakad av ETEC för att skydda både barn och vuxna i endemiska länder och resenärer till högriskdestinationer.

Vi distribuerar ett brett sortiment av biologiska specialistläkemedel med fokus på vacciner och immunglobuliner.

www.scandinavianbiopharma.se

Vår information på mynewsdesk riktar sig till journalister och media.

Scandinavian biopharma
Industrivägen 1, vån 4
171 48 Solna
Sverige